Message #5 From:
NewsBot Date: August 7, 2005 11:00:00 PM
XNOM News Xenomics CEO Randy White to Present Tr-DNA in American Association of Clinical Chemistry Online Education Seminar; CEO to Field Questions on Company Plan to Commercialize Revolutionary Diagnostic Testing Technology During Interactive Program
NEW YORK--(BUSINESS WIRE)--Aug. 8, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has announced that CEO Dr. Randy White will be leading an online, interactive discussion at 1 PM EST, on Tuesday, August 9, to discuss the science behind the Company's Transrenal-DNA technology platform and efforts to develop a new category of breakthrough medical diagnostic tests.
The program is part of an ongoing public education series entitled "Expert Access," produced once a month by the American Association for Clinical Chemistry (AACC), the premier scientific professional association dedicated to the study and practice of clinical chemistry and molecular diagnostics. In advance of Tuesday's presentation, an online electronic presentation on Xenomics' Tr-DNA technology platform is currently available for viewing at the AACC website.
Tuesday's hour-long segment will feature Dr. White in an interactive discussion about Xenomics' pioneering science in Tr-DNA. Based on this proprietary technology platform, the Company is developing a range of novel, fully noninvasive and highly accurate medical diagnostic tests that have the potential to revolutionize medical care across several multi-billion dollar global commercial healthcare markets.
"It is a privilege to be invited by the American Association of Clinical Chemistry to discuss the scientific basis of Transrenal-DNA for the August edition of Expert Access," said Dr. Randy White, Xenomics CEO. "This segment is an opportunity for laboratory experts, biotechnology investors and science enthusiasts to learn about the exciting diagnostic potential of Xenomics' noninvasive Tr-DNA testing technology. It is always a pleasure to tell people about our pioneering technology which is potentially safer, simpler and more cost effective than many current methods." Supplemental scientific background on Tr-DNA technology and Xenomics will also be made available on AACC's web page during the segment.
Tr-DNA refers to fragments of DNA circulating through the body as a result of normal cell death that eventually pass through the kidneys and collect in urine. Using a safe and simple random urine collection, Xenomics' technology has the potential to provide accurate detection of a wide range of disease conditions, including infectious disease such as HIV, tuberculosis and malaria, and fetal genetic abnormalities such as Down syndrome. Xenomics scientists were the first to discover Tr-DNA and the Company has exclusive control of the technology through issued patents in the U.S. and Europe.
AACC's monthly "Expert Access" series covers relevant, timely clinical chemistry and molecular biology topics and is hosted by a range of experts in their respective fields. The public is encouraged to ask questions or submit comments to the host before or during the discussion. To participate in Tuesday's program, or to submit questions beforehand on Monday, please visit http://www.aacc.org/access/molecular/index.asp, and click on "view presentation." The host's answers will then be posted live online during the program.
About American Association for Clinical Chemistry
The American Association for Clinical Chemistry (AACC) is an international scientific/medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry, molecular diagnostics and other clinical laboratory science-related disciplines. For more information, visit http://www.aacc.org.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing, a newly allowed European patent for prenatal genetic testing and nine pending U.S. and European patent applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
